{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T12:17:26Z","timestamp":1783081046986,"version":"3.54.6"},"reference-count":45,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,6,3]],"date-time":"2024-06-03T00:00:00Z","timestamp":1717372800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:sec><jats:title>Introduction<\/jats:title><jats:p>This study explores tumor-induced osteomalacia (TIO) through a case series and literature review, assessing the diagnostic potential of <jats:sup>18<\/jats:sup>F-AlF-NOTA-octreotide (<jats:sup>18<\/jats:sup>F-OC) positron emission tomography\/computed tomography (PET\/CT).<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We analyzed TIO patients who underwent <jats:sup>18<\/jats:sup>F-OC PET\/CT. Parameters such as tumor dimension, the maximum standardized uptake value (SUVmax), the mean standardized uptake value (SUVmean) and metabolic tumor volume (MTV) were meticulously assessed. Clinical features and imaging characteristics pertinent to TIO were reviewed.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>6 patients with clinical suspicion of TIO exhibited hypophosphatemia (0.25 to 0.64 mmol\/L), elevated alkaline phosphatase (ALP) levels (142 to 506 U\/L), and increased parathyroid hormone (PTH) levels (92.9 to 281.7 pg\/mL). Of these patients, two underwent FGF-23 testing, with results of 3185.00 pg\/ml and 17.56 pg\/ml, respectively. Conventional imaging modalities depicted widespread osteoporosis, with several cases demonstrating fractures indicative of osteomalacic and associated pathological fractures. Subsequent <jats:sup>18<\/jats:sup>F-OC PET\/CT facilitated the accurate localization of causative tumors, with histopathological examination confirming the diagnosis of phosphaturic mesenchymal tumor (PMT). The interval from initial clinical presentation to definitive TIO diagnosis spanned approximately 2.5 years (range: 1 - 4 years), with tumors varying in size (maximum diameter: 7.8 to 40.0\u00a0mm), SUVmax (5.47 to 25.69), SUVmean (3.43 to 7.26), and MTV (1.27 to 18.59 cm<jats:sup>3<\/jats:sup>).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>The implementation of whole-body <jats:sup>18<\/jats:sup>F-OC PET\/CT imaging emerges as a critical tool in the identification of occult tumors causing TIO. Future investigations incorporating a broader cohort are imperative to further delineate the diagnostic and therapeutic implications of <jats:sup>18<\/jats:sup>F-OC PET\/CT in managing TIO.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fendo.2024.1400751","type":"journal-article","created":{"date-parts":[[2024,6,3]],"date-time":"2024-06-03T04:34:27Z","timestamp":1717389267000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":3,"title":["18F-AlF-NOTA-octreotide PET\/CT in the localization of tumor-induced osteomalacia: case series and literature review"],"prefix":"10.3389","volume":"15","author":[{"given":"Jing","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,6,3]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1007\/s00223\u2013020-00691\u20136","article-title":"Tumor-induced osteomalacia","volume":"108","author":"Florenzano","year":"2021","journal-title":"Calcif Tissue Int"},{"key":"B2","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1146\/annurev.med.051308.111339","article-title":"Regulation of phosphate homeostasis by PTH, vitamin D, and FGF23","volume":"61","author":"Bergwitz","year":"2010","journal-title":"Annu Rev Med"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1507\/endocrj.EJ17\u20130177","article-title":"Definitive surgical treatment of osteomalacia induced by skull base tumor and determination of the half-life of serum fibroblast growth factor 23","volume":"64","author":"Hana","year":"2017","journal-title":"Endocr J"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1210\/jendso\/bvab099","article-title":"Diagnosis and management of tumor-induced osteomalacia: perspectives from clinical experience","volume":"5","author":"Dahir","year":"2021","journal-title":"J Endocr Soc"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1002\/jbmr.1642","article-title":"Tumor-induced osteomalacia: an important cause of adult-onset hypophosphatemic osteomalacia in China: Report of 39 cases and review of the literature","volume":"27","author":"Jiang","year":"2012","journal-title":"J Bone Miner Res"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1097\/RLU.0000000000002578","article-title":"Clinical application of 18F-alF-NOTA-octreotide PET\/CT in combination with 18F-FDG PET\/CT for imaging neuroendocrine neoplasms","volume":"44","author":"Long","year":"2019","journal-title":"Clin Nucl Med"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.3109\/01913129109016242","article-title":"Review and update: oncogenic osteomalacia-rickets","volume":"15","author":"Weidner","year":"1991","journal-title":"Ultrastruct Pathol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1530\/ERC-11\u20130006","article-title":"Tumor-induced osteomalacia","volume":"18","author":"Chong","year":"2011","journal-title":"Endocr Relat Cancer"},{"key":"B9","doi-asserted-by":"publisher","first-page":"e365","DOI":"10.1016\/S1470\u20132045(18)30276\u20136","article-title":"Oncogenic osteomalacia: diagnosis, localisation, and cure","volume":"19","author":"Wan","year":"2018","journal-title":"Lancet Oncol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.3760\/cma.j.issn.2095\u20132848.2019.08.003","article-title":"Application of 68Ga-DOTATATE PET\/CT imaging combined with MRI in the diagnosis of tumor-induced osteomalacia","volume":"39","author":"Zhang","year":"2019","journal-title":"Chin J Nucl Med Mol Imaging."},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1053\/j.semdp.2019.07.002","article-title":"Phosphaturic mesenchymal tumors: A review and update","volume":"36","author":"Folpe","year":"2019","journal-title":"Semin Diagn Pathol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/j.crad.2007.05.017","article-title":"Giant cell tumour of soft tissue causing oncogenic osteomalacia: report demonstrating the use of octreotide scintigraphy in tumour localization","volume":"63","author":"Harish","year":"2008","journal-title":"Clin Radiol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-012-1474-z","article-title":"Advanced prostate cancer as a cause of oncogenic osteomalacia: an underdiagnosed condition","volume":"20","author":"Mak","year":"2012","journal-title":"Support Care Cancer"},{"key":"B14","doi-asserted-by":"publisher","first-page":"bcr2015213954","DOI":"10.1136\/bcr-2015\u2013213954","article-title":"Hypophosphataemia due to FGF-23 producing B cell non-Hodgkin's lymphoma","volume":"2016","author":"Elderman","year":"2016","journal-title":"BMJ Case Rep"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1097\/00000478\u2013198907000\u201300007","article-title":"Tumor-induced osteomalacia and rickets","volume":"13","author":"Nuovo","year":"1989","journal-title":"Am J Surg Pathol"},{"key":"B16","first-page":"33","article-title":"Osteomalacia with Looser's nodes (Milkman's syndrome) due to a raised resistance to vitamin D acquired about the age of 15 years","volume":"16","author":"McCANCE","year":"1947","journal-title":"Q J Med"},{"key":"B17","article-title":"Rickets following bone tumor","volume":"14","author":"Prader","year":"1959","journal-title":"Helv Paediatr Acta"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1002\/(ISSN)1097-0142","article-title":"Phosphaturic mesenchymal tumors. A polymorphous group causing osteomalacia or rickets","volume":"59","author":"Weidner","year":"1987","journal-title":"Cancer"},{"key":"B19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1097\/00000478\u2013200401000\u201300001","article-title":"Most osteomalacia-associated mesenchymal tumors are a single histopathologic entity: an analysis of 32 cases and a comprehensive review of the literature","volume":"28","author":"Folpe","year":"2004","journal-title":"Am J Surg Pathol"},{"key":"B20","first-page":"239","volume-title":"WHO classification of tumors of soft tissue and bone","author":"Fletcher","year":"2013"},{"key":"B21","doi-asserted-by":"publisher","first-page":"47","DOI":"10.2463\/mrms.2011\u20130006","article-title":"Whole-body MR imaging in detecting phosphaturic mesenchymal tumor (PMT) in tumor-induced hypophosphatemic osteomalacia","volume":"12","author":"Nakanishi","year":"2013","journal-title":"Magn Reson Med Sci"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1097\/RLU.0000000000002012","article-title":"The findings on bone scintigraphy in patients with suspected tumor-induced osteomalacia should not be overlooked","volume":"43","author":"Wang","year":"2018","journal-title":"Clin Nucl Med"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1007\/s00223\u2013022-01005\u20138","article-title":"Tumor-induced osteomalacia: A systematic clinical review of 895 cases","volume":"111","author":"Bosman","year":"2022","journal-title":"Calcif Tissue Int"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1002\/jbmr.1881","article-title":"Tumor localization and biochemical response to cure in tumor-induced osteomalacia","volume":"28","author":"Chong","year":"2013","journal-title":"J Bone Miner Res"},{"key":"B25","article-title":"Somatostatin and vasoactive intestinal peptide receptors in human mesenchymal tumors: in vitro identification","volume":"56","author":"Reubi","year":"1996","journal-title":"Cancer Res"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1016\/s0140\u20136736(02)07846\u20137","article-title":"Localisation of mesenchymal tumours by somatostatin receptor imaging","volume":"359","author":"Jan de Beur","year":"2002","journal-title":"Lancet"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-006-0317-x","article-title":"Are radiogallium-labelled DOTA-conjugated somatostatin analogues superior to those labelled with other radiometals","volume":"34","author":"Antunes","year":"2007","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa010839","article-title":"Octreotide therapy for tumor-induced osteomalacia","volume":"345","author":"Seufert","year":"2001","journal-title":"N Engl J Med"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejrad.2013.04.006","article-title":"Effective detection of the tumors causing osteomalacia using [Tc-99m]-HYNIC-octreotide (99mTc-HYNIC-TOC) whole body scan","volume":"82","author":"Jing","year":"2013","journal-title":"Eur J Radiol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.811209","article-title":"Head-to-head comparison of 68Ga-DOTA-TATE and 68Ga-DOTA-JR11 PET\/CT in patients with tumor-induced osteomalacia: A prospective study","volume":"12","author":"Hou","year":"2022","journal-title":"Front Oncol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1359\/jbmr.060909","article-title":"Oncogenic osteomalacia: exact tumor localization by co-registration of positron emission and computed tomography","volume":"22","author":"Hesse","year":"2007","journal-title":"J Bone Miner Res"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2016\u20132052","article-title":"68Ga-DOTATATE for tumor localization in tumor-induced osteomalacia","volume":"101","author":"El-Maouche","year":"2016","journal-title":"J Clin Endocrinol Metab"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1097\/RLU.0000000000000854","article-title":"68Ga DOTATATE PET\/CT is an accurate imaging modality in the detection of culprit tumors causing osteomalacia","volume":"40","author":"Zhang","year":"2015","journal-title":"Clin Nucl Med"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.21037\/apm-20\u20131466","article-title":"Diagnostic value of 68Ga-DOTA-TATE PET\/CT imaging for tumor- induced osteomalacia","volume":"9","author":"Zhang","year":"2020","journal-title":"Ann Palliat Med"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1007\/s00259\u2013019-04474\u20136","article-title":"Al18F-NOTA-octreotide and 18F-SiFAlin-TATE: two 'new kids on the block' in somatostatin receptor imaging","volume":"46","author":"Goffin","year":"2019","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1186\/s40658\u2013016-0144\u20135","article-title":"Physics of pure and non-pure positron emitters for PET: a review and a discussion","volume":"3","author":"Conti","year":"2016","journal-title":"EJNMMI Phys"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.109.066902","article-title":"A novel facile method of labeling octreotide with (18)F-fluorine","volume":"51","author":"Laverman","year":"2010","journal-title":"J Nucl Med"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1007\/s13277-011-0250-x","article-title":"Optimized labeling of NOTA-conjugated octreotide with F-18","volume":"33","author":"Laverman","year":"2012","journal-title":"Tumour Biol"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.122.264563","article-title":"18F-alF-NOTA-octreotide outperforms 68Ga-DOTATATE\/NOC PET in neuroendocrine tumor patients: Results from a prospective, multicenter study","volume":"64","author":"Pauwels","year":"2023","journal-title":"J Nucl Med"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1007\/s00259\u2013020-04918\u20134","article-title":"[18F]AlF-NOTA-octreotide PET imaging: biodistribution, dosimetry and first comparison with [68Ga]Ga-DOTATATE in neuroendocrine tumour patients","volume":"47","author":"Pauwels","year":"2020","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"B41","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1186\/s13550\u2013023-01003\u20133","article-title":"Prospective comparison of [18F]AlF-NOTA-octreotide PET\/MRI to [68Ga]Ga-DOTATATE PET\/CT in neuroendocrine tumor patients","volume":"13","author":"Boeckxstaens","year":"2023","journal-title":"EJNMMI Res"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgab258","article-title":"Utility of 18F-alF-NOTA-octreotide PET\/CT in the localization of tumor-induced osteomalacia","volume":"106","author":"Long","year":"2021","journal-title":"J Clin Endocrinol Metab"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1155\/2022\/6511179","article-title":"The potential prognostic value of dual-imaging PET parameters based on 18F-FDG and 18F-OC for neuroendocrine neoplasms","volume":"2022","author":"Hou","year":"2022","journal-title":"Mol Imaging"},{"key":"B44","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1017\/S0022215109992313","article-title":"Oncogenic osteomalacia in a patient with an ethmoid sinus tumour","volume":"124","author":"Kurien","year":"2010","journal-title":"J Laryngol Otol"},{"key":"B45","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1186\/s12891\u2013017-1756\u20131","article-title":"Treatment and outcomes of tumor-induced osteomalacia associated with phosphaturic mesenchymal tumors: retrospective review of 12 patients","volume":"18","author":"Zuo","year":"2017","journal-title":"BMC Musculoskelet Disord"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2024.1400751\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,19]],"date-time":"2024-07-19T10:15:07Z","timestamp":1721384107000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2024.1400751\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,3]]},"references-count":45,"alternative-id":["10.3389\/fendo.2024.1400751"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2024.1400751","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,3]]},"article-number":"1400751"}}